Cargando…

High-grade ER-negative tumour breast cancers are characteristic of both very young onset cases and patients with hereditary breast cancer

Detalles Bibliográficos
Autores principales:	Eccles, D, Gerty, S, Simmonds, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3300274/ http://dx.doi.org/10.1186/bcr1582

Ejemplares similares

Prospective Study of Outcome in Sporadic versus Hereditary Breast Cancer: pros and cons of running a cohort study
por: Gerty, SM, et al.
Publicado: (2008)

Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol
por: Eccles, Diana, et al.
Publicado: (2007)

Management of Hereditary Breast Cancer
por: Eccles, D. M., et al.
Publicado: (1999)

The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer
por: Tapper, William, et al.
Publicado: (2008)

Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study
por: Copson, E, et al.
Publicado: (2014)

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
por: Copson, Ellen R, et al.
Publicado: (2018)

Local Recurrence and Breast Oncological Surgery in Young Women With Breast Cancer: The POSH Observational Cohort Study
por: Maishman, Tom, et al.
Publicado: (2017)

Acceleration in the DNA methylation age in breast cancer tumours from very young women
por: Oltra, Sara S., et al.
Publicado: (2019)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
por: Esserman, Laura J, et al.
Publicado: (2005)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer
por: Evans, D Gareth, et al.
Publicado: (2022)

EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours
por: Toosi, Behzad M., et al.
Publicado: (2018)

Tumour spectrum in non-BRCA hereditary breast cancer families in Sweden
por: Wendt, Camilla, et al.
Publicado: (2015)

Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
por: Girgert, Rainer, et al.
Publicado: (2019)

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
por: Shimelis, Hermela, et al.
Publicado: (2018)

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
por: Groenendijk, Floris H., et al.
Publicado: (2019)

Support Vector Machine Classifier for Estrogen Receptor Positive and Negative Early-Onset Breast Cancer
por: Upstill-Goddard, Rosanna, et al.
Publicado: (2013)

Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients
por: McKenzie, Hayley S., et al.
Publicado: (2020)

Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding
por: Irmejs, Arvids, et al.
Publicado: (2017)

Pathology of hereditary breast cancer
por: van der Groep, Petra, et al.
Publicado: (2011)

Hereditary breast and ovarian cancer
por: Gronwald, Jacek, et al.
Publicado: (2008)

The Pathology of Hereditary Breast Cancer
por: Lakhani, Sunil R.
Publicado: (1999)

The Pathology of Hereditary Breast Cancer
por: Honrado, Emiliano, et al.
Publicado: (2004)

Prophylaxis of hereditary breast cancer
por: de Groot, Jolien S., et al.
Publicado: (2017)

A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations
por: An, Q, et al.
Publicado: (2010)

MicroRNA profile in very young women with breast cancer
por: Peña-Chilet, Maria, et al.
Publicado: (2014)

Apoptosis/Necrosis Induction by Ultraviolet, in ER Positive and ER Negative Breast Cancer Cell Lines
por: Shokrollahi Barough, Mahdieh, et al.
Publicado: (2015)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
por: Peterlongo, Paolo, et al.
Publicado: (2021)

Weight Loss Intervention in Survivors of ER/PR-negative Breast Cancer
por: Vitolins, Mara Z, et al.
Publicado: (2014)

Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer
por: Einefors, Rickard, et al.
Publicado: (2013)

Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers
por: Gökmen-Polar, Yesim, et al.
Publicado: (2015)

ER-Negative Breast Cancer Is Highly Responsive to Cholesterol Metabolite Signalling
por: Hutchinson, Samantha A, et al.
Publicado: (2019)

Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer
por: Mazumdar, Abhijit, et al.
Publicado: (2022)

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
por: Tovey, S M, et al.
Publicado: (2009)

Complex Landscape of Germline Variants in Brazilian Patients With Hereditary and Early Onset Breast Cancer
por: Torrezan, Giovana T., et al.
Publicado: (2018)

Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women
por: Kadalayil, Latha, et al.
Publicado: (2017)

Breast cancer characteristics in very young Egyptian women ≤35 years
por: Farouk, Omar, et al.
Publicado: (2016)

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
por: Waks, Adrienne G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ffoqvqntds479j857mp8rtlnp